Fresh EU-Wide Challenge To Sovaldi Patent Puts The Spotlight On Drug Pricing Again
Executive Summary
Access to affordable medicines has become a global challenge. A new chapter has been added to the struggle as several EU-based civil society groups join hands to challenge Gillead’s sofosbuvir patent in a bid to increase access to affordable hepatitis C treatment.
You may also be interested in...
European Patent Office Upholds Gilead’s Sofosbuvir Patent
A challenge brought to the European Patent Office that sought to open the door to generic competition to Gilead’s hepatitis C treatment has failed.
Sofosbuvir Patent Challenge Could Highlight Weaknesses In IP Systems
NGOs from across Europe are challenging a patent protecting Gilead’s Sovaldi in an effort to expand patient access to hepatitis C treatments. They say the case will also expose failings in the intellectual property rights system that hinder access to innovation.
Sofosbuvir Patent Challenge Could Highlight Weaknesses In IP Systems
NGOs from across Europe are challenging a patent protecting Gilead’s Sovaldi in an effort to expand patient access to hepatitis C treatments. They say the case will also expose failings in the intellectual property rights system that hinder access to innovation.